| Objective: To explore the efficacy and safety of belizumab in the treatment of renal and blood system damage in patients with systemic lupus erythematosus.Methods: A retrospective analysis was conducted of 52 patients with SLE who received belizumab treatment at the First Affiliated Hospital of Xinjiang Medical University from January 2020 to August 2022.The patient’s case data,clinical characteristics,laboratory indicators,and treatment related adverse events were recorded.Compare and analyze the SLEDAI-2K score,PGA score,laboratory indicators,and hormone dose changes before and after treatment using repeated measures of analysis of variance and non parametric tests.Results: Medical record data of 52 patients:The average age of onset was(29.73±11.70)years old,and the course of disease was(85.15±54.62)months.The average follow-up time during the treatment period with belizumab was(29.23±10.67)weeks,of which 44 patients received treatment with belizumab for more than 24 weeks.The most common organ involvement among patients treated with belizumab was in the renal system [29 cases(55.8%)],followed by the blood system [23 cases(44.2%)].Compared with baseline,after 24 weeks of treatment,there was a statistically significant decrease in SLEDAI-2K score and PGA score(P<0.05),an increase in C3 and C4 levels(P<0.05),a decrease in Ig G,Ig A,and Ig M levels(P<0.05),a decrease in erythrocyte sedimentation rate and C-reactive protein level(P<0.05),and a decrease in prednisone dosage(P<0.05);Among patients with renal system damage,there was a statistically significant difference in 24-hour urine protein levels(P<0.05),while there was no statistically significant difference in creatinine levels(P>0.05).The difference in white blood cell ratio(AGR)levels was statistically significant(P<0.05);There was a statistically significant difference in the levels of white blood cells,and hemoglobin among patients with hematological damage(P<0.05).Conclusion: Belizumab can effectively improve renal function and blood system damage in patients with SLE,reduce the dosage of glucocorticoids used in patients,improve disease activity in SLE,and have a low incidence of adverse events,with high safety. |
